Corrigendum to “HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption” [J Virus Erad 9 (2) (June 2023) 100331]

• Eunice Akinyi Okumu,
• Gail E. Henderson,
• Carol Golin,
• Kriste Kuczynski,
• Nuchanart Q. Ormsby,
• Holly L. Peay

Affiliations

Eunice Akinyi Okumu

Center for AIDS Research (CFAR), University of North Carolina at Chapel Hill, USA

Gail E. Henderson

Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA; Corresponding author.

Carol Golin

Department of Medicine, School of Medicine, Department of Health Behavior, Gillings Global School of Public Health, University of North Carolina at Chapel Hill, USA; Center for AIDS Research (CFAR), University of North Carolina at Chapel Hill, USA

Kriste Kuczynski

Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA

Nuchanart Q. Ormsby

Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA

Holly L. Peay

RTI International, USA